^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Vectibix (panitumumab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Excerpt:
Colorectal cancer...the panel strongly recommends against the use of therapy involving the concurrent combination of an anti-EGFR agent (cetuximab or panitumumab) and an anti-vascular endothelial growth factor (VEGF) agent (bevacizumab).